JNJ · News · 20260914N

RYBREVANT Label Expansion

JOHNSON & JOHNSON · 2026-09-14 · Importance 23 · Surprise 24

Johnson & Johnson reported Phase 2b COPERNICUS findings for subcutaneous RYBREVANT FASPRO plus LAZCLUZE in previously untreated advanced EGFR-mutated non-small cell lung cancer. The regimen used less frequent dosing and prophylactic strategies, with low rates of rash, blood clots, and administration-related reactions. Fewer than 1% of patients discontinued treatment because of treatment-related events at one year, supporting the subcutaneous formulation’s treatment-experience positioning.

Key facts

• Johnson & Johnson announced new Phase 2b COPERNICUS results showing fewer than 1% of patients discontinued RYBREVANT FASPRO plus LAZCLUZE due to treatment-related events at one year. source
• Johnson & Johnson reported low rates of rash, blood clots and administration-related reactions with subcutaneous RYBREVANT FASPRO plus LAZCLUZE when used with prophylactic strategies. source